ГОРМОНАЛЬНАЯ РЕФРАКТЕРНОСТЬ ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ И ЕЕ РАЗВИТИЕ НА ФОНЕ АНТИАНДРОГЕННОЙ ТЕРАПИИ

Mechanisms of development of hormone refractory prostate cancer currently not fully understood. Materials and methods: treatment results of 135 prostate cancer patients underwent subcapsular orchiectomy. Results: hormone resistance registered at 38 (28.15%) patients, were sensitive to anti-androgenic therapy 97 (71.85%) patients. There are reliable differences between the probability of development of hormone refractory and the patient's age, disease stage and degree of tumor cell differentiation. Conclusion: с linical developed, laboratory and pathomorphological criteria, the use of which may reliably predict the likelihood of hormone refractory patients with prostate cancer on the background of antiandrogenic treatment.